This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMRX vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. NBIX: Which Stock Is the Better Value Option?
Company News for Dec 13, 2019
by Zacks Equity Research
Companies in the news are: FB, AMRX, LMPX, TNXP
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals (AMRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Amneal Pharmaceuticals (AMRX) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -69.23% and -4.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -40.00% and -6.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT or AMRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. AMRX: Which Stock Is the Better Value Option?
Amneal (AMRX) Down on Guidance Update & Restructuring Plan
by Zacks Equity Research
Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.
Amneal Pharmaceuticals (AMRX) Misses Q1 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down
by Zacks Equity Research
A U.S. appeals court declines J&J's (JNJ) request to prevent the launch of generic versions of Zytiga. Stock down more than 3%.
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.
Lannett Set to Lose Distribution Agreement With Key Supplier
by Zacks Equity Research
Lannett Company's (LCI) distribution agreement with key supplier, Jerome Stevens Pharmaceuticals, not to be renewed on expiry. Shares plunge.
Company News For Aug 21, 2018
by Zacks Equity Research
Companies In The News are: EL,COP,PX,AMRX
Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 4.35% and -0.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?